2012
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overApoptosisApoptosis Regulatory ProteinsBlotting, WesternCalcium-Binding ProteinsCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic VectorsHumansKaplan-Meier EstimateLentivirusMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerRNA, Small InterferingStatistics, NonparametricTransfectionConceptsEpithelial ovarian cancerProgression-free survivalOvarian cancer progressionOvarian cancer cellsOvarian cancerFree survivalOverall survivalIndependent predictorsKaplan-Meier survival analysisEpithelial ovarian cancer tissuesMetastatic ovarian cancer cellsCancer progressionPDCD6 expressionResidual tumor sizeClinical pathological factorsEpithelial ovarian cancer correlatesCancer cellsOvarian cancer correlatesOvarian cancer tissuesHistologic typeClinical progressionTumor sizeDisease stageTumor gradeCancer correlates
2005
A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer
McClusky D, Chu Q, Yu H, DeBenedetti A, Johnson L, Meschonat C, Turnage R, McDonald J, Abreo F, Li B. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer. Annals Of Surgery 2005, 123: 278-286. PMID: 16192819, PMCID: PMC1402342, DOI: 10.1097/01.sla.0000184224.55949.90.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBlotting, WesternBreast NeoplasmsElectrophoresis, Polyacrylamide GelEukaryotic Initiation Factor-4EFemaleFollow-Up StudiesHumansIncidenceLymph NodesLymphatic MetastasisMastectomy, Extended RadicalMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesRisk FactorsSurvival RateConceptsNode-positive breast cancerBreast cancerCancer recurrenceHighest tertileEIF4E overexpressionProspective trialNodal statusHigher cancer recurrence rateCancer-related death rateCox proportional hazards modelNode-positive diseaseKaplan-Meier methodCancer recurrence rateLog-rank testCancer-related deathProportional hazards modelRelative risk increaseHigh eIF4E overexpressionRelative risk calculationsMedian followDisease recurrenceIndependent predictorsIntermediate tertileNoncancer patientsProspective study
2002
Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome
Li B, Gruner J, Abreo F, Johnson L, Yu H, Nawas S, McDonald J, DeBenedetti A. Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome. Annals Of Surgery 2002, 235: 732-739. PMID: 11981220, PMCID: PMC1422500, DOI: 10.1097/00000658-200205000-00016.Peer-Reviewed Original ResearchConceptsCancer-related deathCancer recurrenceRelative riskBreast cancerIndependent predictorsReceptor statusProtein elevationHigh eIF4EMenopausal statusTumor sizeTumor gradeHigher cancer recurrence rateImportant independent prognostic markerKaplan-Meier survival curvesCox proportional hazards modelStage 1Progesterone receptor statusBreast cancer outcomesSmall retrospective studiesStage of diseaseEstrogen receptor statusCancer recurrence rateIndependent prognostic markerLog-rank testBreast cancer recurrence
1998
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
Levesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceAntibody SpecificityBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDisease-Free SurvivalFemaleFluorescent Antibody TechniqueHumansLymphatic MetastasisMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisReceptors, EstrogenReceptors, ProgesteroneRecurrenceSensitivity and SpecificityTime FactorsTumor Suppressor Protein p53ConceptsP53 proteinItalian breast cancer patientsProgesterone receptor expression statusMultivariate Cox regression analysisP53-negative patientsP53-positive patientsReceptor expression statusDisease-free survivalLymph node statusSteroid hormone receptor analysisCox regression analysisBreast cancer patientsEstrogen receptor expressionHormone receptor analysisCM-1 antibodySensitive immunofluorometric assayBreast cancer prognosisP53 protein accumulationOverall survivalPatient ageIndependent predictorsHistologic typeNode statusPrognostic valueShort patients